The basis of the agreement between Apeiron and Columbia Technology Ventures is a patented technology enabling the inhibition of the immune checkpoint Cbl-b in T-lymphocytes in cancer treatment. Thanks to this agreement, Apeiron is given worldwide exclusive rights to use this technology to develop and commercialize active cellular immunotherapies and thus further expand its own patent portfolio for the Cbl-b blockade.
The project is based on the research work carried out by Josef Penninger, who is the Head of the Institute for Molecular Biotechnology (IMBA) in Vienna. A patent was granted. However, at about the same time, a research group at Columbia University also received a patent in this area. In order to avoid future conflicts, Apeiron has striven to obtain the relevant licensing, according to Apeiron Managing Director Hans Loibner.